Title: HOUSE BILL No. 2218
Official Title: HOUSE BILL No. 2218
Number of Sections: 1
Source: versions - As introduced
Media Type: application/pdf
Strikethrough Detection: 10 sections found

================================================================================

Section 1:
Session of 2025
By Committee on Health and Human Services
Requested by Steve Kearney on behalf of Compass Pathways
2-3
1 AN ACT concerning the uniform controlled substances act; defining
2 psilocybin to exclude the pharmaceutical composition of crystalline
3 polymorph psilocybin; adding crystalline polymorph psilocybin to
4 schedule IV; amending K.S.A. 2024 Supp. 65-4101 and 65-4111 and
5 repealing the existing sections.
6
7 Be it enacted by the Legislature of the State of Kansas:
8 Section 1. On and after the date of publication in the Kansas register
9 of the certification prescribed in section 3, K.S.A. 2024 Supp. 65-4101 is
10 hereby amended to read as follows: 65-4101. As used in this act:
11 (a) "Administer" means the direct application of a controlled
12 substance, whether by injection, inhalation, ingestion or any other means,
13 to the body of a patient or research subject by:
14 (1) A practitioner or pursuant to the lawful direction of a practitioner;
15 or
16 (2) the patient or research subject at the direction and in the presence
17 of the a practitioner.
18 (b) "Agent" means an authorized person who acts on behalf of or at
19 the direction of a manufacturer, distributor or dispenser. "Agent" does not
20 include a common carrier, public warehouseman or employee of the carrier
21 or warehouseman.
22 (c) "Application service provider" means an entity that sells
23 electronic prescription or pharmacy prescription applications as a hosted
24 service where the entity controls access to the application and maintains
25 the software and records on its server.
26 (d) "Board" means the state board of pharmacy.
27 (e) "Bureau" means the bureau of narcotics and dangerous drugs, of
28 the United States department of justice, or its successor agency.
29 (f) "Controlled substance" means any drug, substance or immediate
30 precursor included in any of the schedules designated in K.S.A. 65-4105,
31 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
32 (g) (1) "Controlled substance analog" means a substance that is
33 intended for human consumption, and at least one of the following:
34 (A) The chemical structure of the substance is substantially similar to
35 the chemical structure of a controlled substance listed in or added to the
HB 2218 2
1 schedules designated in K.S.A. 65-4105 or 65-4107, and amendments
2 thereto;
3 (B) the substance has a stimulant, depressant or hallucinogenic effect
4 on the central nervous system substantially similar to the stimulant,
5 depressant or hallucinogenic effect on the central nervous system of a
6 controlled substance included in the schedules designated in K.S.A. 65-
7 4105 or 65-4107, and amendments thereto; or
8 (C) with respect to a particular individual, such individual represents
9 or intends the substance to have a stimulant, depressant or hallucinogenic
10 effect on the central nervous system substantially similar to the stimulant,
11 depressant or hallucinogenic effect on the central nervous system of a
12 controlled substance included in the schedules designated in K.S.A. 65-
13 4105 or 65-4107, and amendments thereto.
14 (2) "Controlled substance analog" does not include:
15 (A) A controlled substance;
16 (B) a substance for which there is an approved new drug application;
17 or
18 (C) a substance with respect to which an exemption is in effect for
19 investigational use by a particular person under section 505 of the federal
20 food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with
21 respect to the substance is permitted by the exemption.
22 (h) "Counterfeit substance" means a controlled substance that, or the
23 container or labeling of which, without authorization bears the trademark,
24 trade name or other identifying mark, imprint, number or device or any
25 likeness thereof of a manufacturer, distributor or dispenser other than the
26 person who in fact manufactured, distributed or dispensed the substance.
27 (i) "Cultivate" means the planting or promotion of growth of five or
28 more plants that contain or can produce controlled substances.
29 (j) "DEA" means the U.S. department of justice, drug enforcement
30 administration.
31 (k) "Deliver" or "delivery" means the actual, constructive or
32 attempted transfer from one person to another of a controlled substance,
33 whether or not there is an agency relationship.
34 (l) "Dispense" means to deliver a controlled substance to an ultimate
35 user or research subject by or pursuant to the lawful order of a practitioner,
36 including the packaging, labeling or compounding necessary to prepare the
37 substance for that delivery, or pursuant to the prescription of a mid-level
38 practitioner.
39 (m) "Dispenser" means a practitioner or pharmacist who dispenses, or
40 a physician assistant who has authority to dispense prescription-only drugs
41 in accordance with K.S.A. 65-28a08(b), and amendments thereto.
42 (n) "Distribute" means to deliver other than by administering or
43 dispensing a controlled substance.
HB 2218 3
1 (o) "Distributor" means a person who distributes.
2 (p) (1) "Drug" means substances:
3 (A) Recognized as drugs in the official United States pharmacopeia,
4 official homeopathic pharmacopoeia of the United States or official
5 national formulary or any supplement to any of them;
6 (B) intended for use in the diagnosis, cure, mitigation, treatment or
7 prevention of disease in human or animals;
8 (C) other than food intended to affect the structure or any function of
9 the body of human or animals; and
10 (D) intended for use as a component of any article specified in
11 subparagraph (A), (B) or (C).
12 (2) "Drug" does not include devices or their components, parts or
13 accessories.
14 (q) "Immediate precursor" means a substance that the board has
15 found to be and by rule and regulation designates as being the principal
16 compound commonly used or produced primarily for use and that is an
17 immediate chemical intermediary used or likely to be used in the
18 manufacture of a controlled substance, the control of which is necessary to
19 prevent, curtail or limit manufacture.
20 (r) "Electronic prescription" means an electronically prepared
21 prescription that is authorized and transmitted from the prescriber to the
22 pharmacy by means of electronic transmission.
23 (s) "Electronic prescription application" means software that is used
24 to create electronic prescriptions and that is intended to be installed on the
25 prescriber's computers and servers where access and records are controlled
26 by the prescriber.
27 (t) "Electronic signature" means a confidential personalized digital
28 key, code, number or other method for secure electronic data transmissions
29 that identifies a particular person as the source of the message,
30 authenticates the signatory of the message and indicates the person's
31 approval of the information contained in the transmission.
32 (u) "Electronic transmission" means the transmission of an electronic
33 prescription, formatted as an electronic data file, from a prescriber's
34 electronic prescription application to a pharmacy's computer, where the
35 data file is imported into the pharmacy prescription application.
36 (v) "Electronically prepared prescription" means a prescription that is
37 generated using an electronic prescription application.
38 (w) "Facsimile transmission" or "fax transmission" means the
39 transmission of a digital image of a prescription from the prescriber or the
40 prescriber's agent to the pharmacy. "Facsimile transmission" includes, but
41 is not limited to, transmission of a written prescription between the
42 prescriber's fax machine and the pharmacy's fax machine;, transmission of
43 an electronically prepared prescription from the prescriber's electronic
HB 2218 4
1 prescription application to the pharmacy's fax machine, computer or
2 printer; or transmission of an electronically prepared prescription from the
3 prescriber's fax machine to the pharmacy's fax machine, computer or
4 printer.
5 (x) "Intermediary" means any technology system that receives and
6 transmits an electronic prescription between the prescriber and the
7 pharmacy.
8 (y) "Isomer" means all enantiomers and diastereomers.
9 (z) "Manufacture" means the production, preparation, propagation,
10 compounding, conversion or processing of a controlled substance either
11 directly or indirectly or by extraction from substances of natural origin or
12 independently by means of chemical synthesis or by a combination of
13 extraction and chemical synthesis and includes any packaging or
14 repackaging of the substance or labeling or relabeling of its container,
15 except that this term "manufacture" does not include the preparation or
16 compounding of a controlled substance by an individual for the
17 individual's own lawful use or the preparation, compounding, packaging or
18 labeling of a controlled substance:
19 (1) By a practitioner or the practitioner's agent pursuant to a lawful
20 order of a practitioner as an incident to the practitioner's administering or
21 dispensing of a controlled substance in the course of the practitioner's
22 professional practice; or
23 (2) by a practitioner or by the practitioner's authorized agent under
24 such practitioner's supervision for the purpose of or as an incident to
25 research, teaching or chemical analysis or by a pharmacist or medical care
26 facility as an incident to dispensing of a controlled substance.
27 (aa) "Marijuana" means all parts of all varieties of the plant Cannabis
28 whether growing or not, the seeds thereof, the resin extracted from any
29 part of the plant and every compound, manufacture, salt, derivative,
30 mixture or preparation of the plant, its seeds or resin. It does not include:
31 (1) The mature stalks of the plant, fiber produced from the stalks, oil
32 or cake made from the seeds of the plant, any other compound,
33 manufacture, salt, derivative, mixture or preparation of the mature stalks,
34 except the resin extracted therefrom, fiber, oil or cake or the sterilized seed
35 of the plant that is incapable of germination;
36 (2) any substance listed in schedules II through V of the uniform
37 controlled substances act;
38 (3) drug products approved by the United States food and drug
39 administration as of the effective date of this act;
40 (4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-
41 2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or
42 (5) industrial hemp as defined in K.S.A. 2-3901, and amendments
43 thereto, when cultivated, produced, possessed or used for activities
HB 2218 5
1 authorized by the commercial industrial hemp act.
2 (bb) "Medical care facility" shall have the meaning ascribed to that
3 term means the same as defined in K.S.A. 65-425, and amendments
4 thereto.
5 (cc) "Mid-level practitioner" means a certified nurse-midwife
6 engaging in the independent practice of midwifery under the independent
7 practice of midwifery act, an advanced practice registered nurse issued a
8 license pursuant to K.S.A. 65-1131, and amendments thereto, who has
9 authority to prescribe drugs under K.S.A. 65-1130, and amendments
10 thereto, or a physician assistant licensed under the physician assistant
11 licensure act who has authority to prescribe drugs pursuant to a written
12 agreement with a supervising physician under K.S.A. 65-28a08, and
13 amendments thereto.
14 (dd) "Narcotic drug" means any of the following whether produced
15 directly or indirectly by extraction from substances of vegetable origin or
16 independently by means of chemical synthesis or by a combination of
17 extraction and chemical synthesis:
18 (1) Opium and opiate and any salt, compound, derivative or
19 preparation of opium or opiate;
20 (2) any salt, compound, isomer, derivative or preparation thereof that
21 is chemically equivalent or identical with any of the substances referred to
22 in paragraph (1) but not including the isoquinoline alkaloids of opium;
23 (3) opium poppy and poppy straw;
24 (4) coca leaves and any salt, compound, derivative or preparation of
25 coca leaves, and any salt, compound, isomer, derivative or preparation
26 thereof that is chemically equivalent or identical with any of these
27 substances, but not including decocainized coca leaves or extractions of
28 coca leaves that do not contain cocaine or ecgonine.
29 (ee) "Opiate" means any substance having an addiction-forming or
30 addiction-sustaining liability similar to morphine or being capable of
31 conversion into a drug having addiction-forming or addiction-sustaining
32 liability. It does not include, unless specifically designated as controlled
33 under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer
34 of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does
35 include its racemic and levorotatory forms.
36 (ff) "Opium poppy" means the plant of the species Papaver
37 somniferum l. except its seeds.
38 (gg) "Person" means an individual, corporation, government, or
39 governmental subdivision or agency, business trust, estate, trust,
40 partnership or association or any other legal entity.
41 (hh) "Pharmacist" means any natural person licensed under K.S.A.
42 65-1625 et seq., and amendments thereto, to practice pharmacy.
43 (ii) "Pharmacist intern" means: (1) A student currently enrolled in an
HB 2218 6
1 accredited pharmacy program; (2) a graduate of an accredited pharmacy
2 program serving such person's internship; or (3) a graduate of a pharmacy
3 program located outside of the United States that is not accredited and who
4 had successfully passed equivalency examinations approved by the board.
5 (jj) "Pharmacy prescription application" means software that is used
6 to process prescription information, is installed on a pharmacy's computers
7 and servers, and is controlled by the pharmacy.
8 (kk) "Poppy straw" means all parts, except the seeds, of the opium
9 poppy, after mowing.
10 (ll) "Practitioner" means a person licensed to practice medicine and
11 surgery, dentist, podiatrist, veterinarian, optometrist, or scientific
12 investigator or other person authorized by law to use a controlled
13 substance in teaching or chemical analysis or to conduct research with
14 respect to a controlled substance.
15 (mm) "Prescriber" means a practitioner or a mid-level practitioner.
16 (nn) "Production" includes the manufacture, planting, cultivation,
17 growing or harvesting of a controlled substance.
18 (oo) "Psilocybin" does not include the pharmaceutical composition of
19 crystalline polymorph psilocybin, known as COMP 360 or any such trade
20 name approved by the United States food and drug administration.
21 (pp) "Readily retrievable" means that records kept by automatic data
22 processing applications or other electronic or mechanized recordkeeping
23 systems can be separated out from all other records within a reasonable
24 time not to exceed 48 hours of a request from the board or other authorized
25 agent or that hard-copy records are kept on which certain items are
26 asterisked, redlined or in some other manner visually identifiable apart
27 from other items appearing on the records.
28 (pp)(qq) "Ultimate user" means a person who lawfully possesses a
29 controlled substance for such person's own use or for the use of a member
30 of such person's household or for administering to an animal owned by
31 such person or by a member of such person's household.
32 Sec. 2. On and after the date of publication in the Kansas register of
33 the notice prescribed in section 3, K.S.A. 2024 Supp. 65-4111 is hereby
34 amended to read as follows: 65-4111. (a) The controlled substances listed
35 in this section are included in schedule IV and the number set forth
36 opposite each drug or substance is the DEA controlled substances code
37 that has been assigned to it.
38 (b) Any material, compound, mixture or preparation that contains any
39 quantity of the following substances including its salts, isomers and salts
40 of isomers whenever the existence of such salts, isomers and salts of
41 isomers is possible within the specific chemical designation and having a
42 potential for abuse associated with a depressant effect on the central
43 nervous system:
HB 2218 7
1 (1) Alprazolam.............................................................................2882
2 (2) Barbital...................................................................................2145
3 (3) Brexanolone...........................................................................2400
4 (4) Bromazepam .........................................................................2748
5 (5) Camazepam............................................................................2749
6 (6) Carisoprodol...........................................................................8192
7 (7) Chloral betaine.......................................................................2460
8 (8) Chloral hydrate.......................................................................2465
9 (9) Chlordiazepoxide...................................................................2744
10 (10) Clobazam................................................................................2751
11 (11) Clonazepam............................................................................2737
12 (12) Clorazepate.............................................................................2768
13 (13) Clotiazepam............................................................................2752
14 (14) Cloxazolam............................................................................2753
15 (15) Daridorexant...........................................................................2410
16 (16) Delorazepam..........................................................................2754
17 (17) Diazepam................................................................................2765
18 (18) Dichloralphenazone................................................................2467
19 (19) Estazolam...............................................................................2756
20 (20) Ethchlorvynol.........................................................................2540
21 (21) Ethinamate..............................................................................2545
22 (22) Ethyl loflazepate.....................................................................2758
23 (23) Fludiazepam...........................................................................2759
24 (24) Flunitrazepam.........................................................................2763
25 (25) Flurazepam.............................................................................2767
26 (26) Fospropofol............................................................................2138
27 (27) Halazepam..............................................................................2762
28 (28) Haloxazolam..........................................................................2771
29 (29) Ketazolam..............................................................................2772
30 (30) Lemborexant..........................................................................2245
31 (31) Loprazolam............................................................................2773
32 (32) Lorazepam..............................................................................2885
33 (33) Lormetazepam........................................................................2774
34 (34) Mebutamate............................................................................2800
35 (35) Medazepam............................................................................2836
36 (36) Meprobamate..........................................................................2820
37 (37) Methohexital..........................................................................2264
38 (38) Methylphenobarbital (mephobarbital)...................................2250
39 (39) Midazolam..............................................................................2884
40 (40) Nimetazepam..........................................................................2837
41 (41) Nitrazepam.............................................................................2834
42 (42) Nordiazepam..........................................................................2838
43 (43) Oxazepam...............................................................................2835
HB 2218 8
1 (44) Oxazolam...............................................................................2839
2 (45) Paraldehyde............................................................................2585
3 (46) Petrichloral.............................................................................2591
4 (47) Phenobarbital..........................................................................2285
5 (48) Pinazepam..............................................................................2883
6 (49) Prazepam................................................................................2764
7 (50) Quazepam...............................................................................2881
8 (51) Remimazolam........................................................................2846
9 (52) Temazepam.............................................................................2925
10 (53) Tetrazepam.............................................................................2886
11 (54) Triazolam...............................................................................2887
12 (55) Zolpidem................................................................................2783
13 (56) Zaleplon..................................................................................2781
14 (57) Zopiclone................................................................................2784
15 (58) Alfaxalone..............................................................................2731
16 (59) Suvorexant..............................................................................2223
17 (c) Any material, compound, mixture or preparation that contains any
18 quantity of lorcaserin (1625), including its salts, isomers and salts of such
19 isomers, whenever the existence of such salts, isomers and salts of isomers
20 is possible (21 U.S.C. § 812; 21 C.F.R. § 1308.14).
21 (d) Unless specifically excepted or unless listed in another schedule,
22 any material, compound, mixture or preparation that contains any quantity
23 of the following substances having a stimulant effect on the central
24 nervous system, including its salts, isomers (whether optical, position or
25 geometric) and salts of such isomers whenever the existence of such salts,
26 isomers and salts of isomers is possible within the specific chemical
27 designation:
28 (1) Cathine ((+)-norpseudoephedrine).........................................1230
29 (2) Diethylpropion.......................................................................1610
30 (3) Fencamfamin..........................................................................1760
31 (4) Fenproporex...........................................................................1575
32 (5) Mazindol................................................................................1605
33 (6) Mefenorex..............................................................................1580
34 (7) Pemoline (including organometallic
35 complexes and chelates thereof)............................................1530
36 (8) Phentermine............................................................................1640
37 The provisions of subsection (d)(8) shall expire on the date
38 phentermine and its salts and isomers are removed from schedule IV of the
39 federal controlled substances act (21 U.S.C. § 812; 21 C.F.R. § 1308.14).
40 (9) Pipradrol.................................................................................1750
41 (10) Serdexmethylphenidate..........................................................1729
42 (11) SPA((-)-1-dimethylamino-1, 2-diphenylethane)....................1635
43 (12) Sibutramine............................................................................1675
HB 2218 9
1 (13) Solriamfetol (2-amino-3-phenylpropyl carbamate;
2 benzenepropanol, beta-amino-, carbamate (ester))................1650
3 (14) Mondafinil..............................................................................1680
4 (e) Unless specifically excepted or unless listed in another schedule,
5 any material, compound, mixture or preparation that contains any quantity
6 of the following, including salts thereof:
7 (1) Pentazocine............................................................................9709
8 (2) Butorphanol (including its optical isomers)...........................9720
9 (3) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-
10 dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-
11 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its
12 optical isomers) and its salts, isomers, and salts of isomers..9725
13 (f) Unless specifically excepted or unless listed in another schedule,
14 any material, compound, mixture or preparation containing any of the
15 following narcotic drugs, or their salts calculated as the free anhydrous
16 base or alkaloid, in limited quantities as set forth below:
17 (1) Not more than 1 milligram of difenoxin and not less than 25
18 micrograms of atropine sulfate per dosage unit.....................9167
19 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-
20 3-methyl-2-propion-oxybutane).............................................9278
21 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol,
22 its salts, optical and geometric isomers and salts of these isomers
23 (including tramadol)...............................................................9752
24 (g) Butyl nitrite and its salts, isomers, esters, ethers or their salts.
25 (h) Any pharmaceutical composition of crystalline polymorph
26 psilocybin approved by the United States food and drug administration.
27 (i) The board may except by rule and regulation any compound,
28 mixture or preparation containing any depressant substance listed in
29 subsection (b) from the application of all or any part of this act if the
30 compound, mixture or preparation contains one or more active medicinal
31 ingredients not having a depressant effect on the central nervous system,
32 and if the admixtures are included therein in combinations, quantity,
33 proportion or concentration that vitiate the potential for abuse of the
34 substances that have a depressant effect on the central nervous system.
35 New Sec. 3. When the pharmaceutical composition of crystalline
36 polymorph psilocybin is approved as a drug product by the United States
37 food and drug administration, the attorney general shall certify such drug
38 product's approval to the secretary of state within seven days after its
39 approval. Upon receipt of such certification, the secretary of state shall
40 publish such certification in the Kansas register.
41 Sec. 4. On and after the date of publication in the Kansas register of
42 the certification prescribed in section 3, K.S.A. 2024 Supp. 65-4101 and
43 K.S.A. 65-4111 is hereby repealed.
HB 2218 10
1 Sec. 5. This act shall take effect and be in force from and after its
2 publication in the statute book.
[DELETED: AppsrBSo0h1(" ms te dt an of a c2s3t4(5o6(7o8(9t0i1o2(n se p" ms an ey tt s3e4s5t6(7(8t9(0p162(3i4(5t]
[DELETED: 8st(odc4(o0e1d2c344(5(6(7o8(9i0f1r2(3c4t5l6p7(8m9(0a1(" or "" ms te a, ce o2a3w4(5u6i7s8p9(0a1i2(3d]
[DELETED: 8(((ol s n(p(t0(1s2(3a4(5f6c7ie cl i ud or l t be ud i t8m9p0(c p" ms an ey p1p2p3(4t5p6b7(8k9tt is a pr pn as te se of te m0a1a2(3p4e5d6(7g8(e t" or "x t" ms t9t0p1i2p3a]
[DELETED: 8pppp(ts an ec pn bn te pr ad tp((0c1d2i3en ad cl ss ad is ay pg o4r5e6cg of a cd se by an il fr t7i8l9(0o1d2p3(4s5r6f7(8w9p0m1(2or ce me fm te ss of te p, ay or c3m4e5o6(7c8(9a0(122(3t, wn c, p, pd o ud fr a]
[DELETED: 8a(t me  it(l p" ms a cd nepla0t1l2a3a4(5d6i7e8(m ad oe ad ay s, c, de o9p0(1i2i3(4(5c6t7s8c9(0a1c2l3u4o5i6(m p" ms te pt of te ss P7s8(" ms an i, c, g, o9gl sn or a, bs t, e, t0p1(263(]
[DELETED: 8apph(ta(p0(1s, d, p, v, o, or s2ir r r n a bw  ua 3s4r5(6(7g8(9c0n1(2p3s4t5a6a7f8(9c0o1s2S3t4a5i6o7t8(9q0o1i2p3n]
[DELETED: 8()A()B()B()B( C( C( C( C( C0( C1( C2( C3( C4( C5( D6()D7( D8( D9( E0( E1( E2( E3( F4( F5( F6( F7( H8( H9( K0( L1()L2()L3( L4( M5( M6( M7( M8( M9( M0( N1( N2( N3( O]
[DELETED: 8( O( P( P( P( P( P( Q( R( T0( T1( T2( Z3( Z4( Z5( A6( S7(8q9i0i1(2a3o4n5g6i7d8()C9()D0()F1()F2()M3()M4()P5c6()P7Te ps of sn () sl ee on te d8p9f0()P1()S2()S3()S]
[DELETED: 8()Sb()M(ao()P()B()E0d1y2o..3(4a5f6b7()N8m9()D031()22i3(4(5(y pl cn of ce p6p7(8m9s0c1i2a3p4s5N6p7f8p9a0p1S2t3K]
[DELETED: 81Sp]


================================================================================

Raw Text:
Session of 2025
HOUSE BILL No. 2218
By Committee on Health and Human Services
Requested by Steve Kearney on behalf of Compass Pathways
2-3
1 AN ACT concerning the uniform controlled substances act; defining
2 psilocybin to exclude the pharmaceutical composition of crystalline
3 polymorph psilocybin; adding crystalline polymorph psilocybin to
4 schedule IV; amending K.S.A. 2024 Supp. 65-4101 and 65-4111 and
5 repealing the existing sections.
6
7 Be it enacted by the Legislature of the State of Kansas:
8 Section 1. On and after the date of publication in the Kansas register
9 of the certification prescribed in section 3, K.S.A. 2024 Supp. 65-4101 is
10 hereby amended to read as follows: 65-4101. As used in this act:
11 (a) "Administer" means the direct application of a controlled
12 substance, whether by injection, inhalation, ingestion or any other means,
13 to the body of a patient or research subject by:
14 (1) A practitioner or pursuant to the lawful direction of a practitioner;
15 or
16 (2) the patient or research subject at the direction and in the presence
17 of the a practitioner.
18 (b) "Agent" means an authorized person who acts on behalf of or at
19 the direction of a manufacturer, distributor or dispenser. "Agent" does not
20 include a common carrier, public warehouseman or employee of the carrier
21 or warehouseman.
22 (c) "Application service provider" means an entity that sells
23 electronic prescription or pharmacy prescription applications as a hosted
24 service where the entity controls access to the application and maintains
25 the software and records on its server.
26 (d) "Board" means the state board of pharmacy.
27 (e) "Bureau" means the bureau of narcotics and dangerous drugs, of
28 the United States department of justice, or its successor agency.
29 (f) "Controlled substance" means any drug, substance or immediate
30 precursor included in any of the schedules designated in K.S.A. 65-4105,
31 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
32 (g) (1) "Controlled substance analog" means a substance that is
33 intended for human consumption, and at least one of the following:
34 (A) The chemical structure of the substance is substantially similar to
35 the chemical structure of a controlled substance listed in or added to the

HB 2218 2
1 schedules designated in K.S.A. 65-4105 or 65-4107, and amendments
2 thereto;
3 (B) the substance has a stimulant, depressant or hallucinogenic effect
4 on the central nervous system substantially similar to the stimulant,
5 depressant or hallucinogenic effect on the central nervous system of a
6 controlled substance included in the schedules designated in K.S.A. 65-
7 4105 or 65-4107, and amendments thereto; or
8 (C) with respect to a particular individual, such individual represents
9 or intends the substance to have a stimulant, depressant or hallucinogenic
10 effect on the central nervous system substantially similar to the stimulant,
11 depressant or hallucinogenic effect on the central nervous system of a
12 controlled substance included in the schedules designated in K.S.A. 65-
13 4105 or 65-4107, and amendments thereto.
14 (2) "Controlled substance analog" does not include:
15 (A) A controlled substance;
16 (B) a substance for which there is an approved new drug application;
17 or
18 (C) a substance with respect to which an exemption is in effect for
19 investigational use by a particular person under section 505 of the federal
20 food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with
21 respect to the substance is permitted by the exemption.
22 (h) "Counterfeit substance" means a controlled substance that, or the
23 container or labeling of which, without authorization bears the trademark,
24 trade name or other identifying mark, imprint, number or device or any
25 likeness thereof of a manufacturer, distributor or dispenser other than the
26 person who in fact manufactured, distributed or dispensed the substance.
27 (i) "Cultivate" means the planting or promotion of growth of five or
28 more plants that contain or can produce controlled substances.
29 (j) "DEA" means the U.S. department of justice, drug enforcement
30 administration.
31 (k) "Deliver" or "delivery" means the actual, constructive or
32 attempted transfer from one person to another of a controlled substance,
33 whether or not there is an agency relationship.
34 (l) "Dispense" means to deliver a controlled substance to an ultimate
35 user or research subject by or pursuant to the lawful order of a practitioner,
36 including the packaging, labeling or compounding necessary to prepare the
37 substance for that delivery, or pursuant to the prescription of a mid-level
38 practitioner.
39 (m) "Dispenser" means a practitioner or pharmacist who dispenses, or
40 a physician assistant who has authority to dispense prescription-only drugs
41 in accordance with K.S.A. 65-28a08(b), and amendments thereto.
42 (n) "Distribute" means to deliver other than by administering or
43 dispensing a controlled substance.

HB 2218 3
1 (o) "Distributor" means a person who distributes.
2 (p) (1) "Drug" means substances:
3 (A) Recognized as drugs in the official United States pharmacopeia,
4 official homeopathic pharmacopoeia of the United States or official
5 national formulary or any supplement to any of them;
6 (B) intended for use in the diagnosis, cure, mitigation, treatment or
7 prevention of disease in human or animals;
8 (C) other than food intended to affect the structure or any function of
9 the body of human or animals; and
10 (D) intended for use as a component of any article specified in
11 subparagraph (A), (B) or (C).
12 (2) "Drug" does not include devices or their components, parts or
13 accessories.
14 (q) "Immediate precursor" means a substance that the board has
15 found to be and by rule and regulation designates as being the principal
16 compound commonly used or produced primarily for use and that is an
17 immediate chemical intermediary used or likely to be used in the
18 manufacture of a controlled substance, the control of which is necessary to
19 prevent, curtail or limit manufacture.
20 (r) "Electronic prescription" means an electronically prepared
21 prescription that is authorized and transmitted from the prescriber to the
22 pharmacy by means of electronic transmission.
23 (s) "Electronic prescription application" means software that is used
24 to create electronic prescriptions and that is intended to be installed on the
25 prescriber's computers and servers where access and records are controlled
26 by the prescriber.
27 (t) "Electronic signature" means a confidential personalized digital
28 key, code, number or other method for secure electronic data transmissions
29 that identifies a particular person as the source of the message,
30 authenticates the signatory of the message and indicates the person's
31 approval of the information contained in the transmission.
32 (u) "Electronic transmission" means the transmission of an electronic
33 prescription, formatted as an electronic data file, from a prescriber's
34 electronic prescription application to a pharmacy's computer, where the
35 data file is imported into the pharmacy prescription application.
36 (v) "Electronically prepared prescription" means a prescription that is
37 generated using an electronic prescription application.
38 (w) "Facsimile transmission" or "fax transmission" means the
39 transmission of a digital image of a prescription from the prescriber or the
40 prescriber's agent to the pharmacy. "Facsimile transmission" includes, but
41 is not limited to, transmission of a written prescription between the
42 prescriber's fax machine and the pharmacy's fax machine;, transmission of
43 an electronically prepared prescription from the prescriber's electronic

HB 2218 4
1 prescription application to the pharmacy's fax machine, computer or
2 printer; or transmission of an electronically prepared prescription from the
3 prescriber's fax machine to the pharmacy's fax machine, computer or
4 printer.
5 (x) "Intermediary" means any technology system that receives and
6 transmits an electronic prescription between the prescriber and the
7 pharmacy.
8 (y) "Isomer" means all enantiomers and diastereomers.
9 (z) "Manufacture" means the production, preparation, propagation,
10 compounding, conversion or processing of a controlled substance either
11 directly or indirectly or by extraction from substances of natural origin or
12 independently by means of chemical synthesis or by a combination of
13 extraction and chemical synthesis and includes any packaging or
14 repackaging of the substance or labeling or relabeling of its container,
15 except that this term "manufacture" does not include the preparation or
16 compounding of a controlled substance by an individual for the
17 individual's own lawful use or the preparation, compounding, packaging or
18 labeling of a controlled substance:
19 (1) By a practitioner or the practitioner's agent pursuant to a lawful
20 order of a practitioner as an incident to the practitioner's administering or
21 dispensing of a controlled substance in the course of the practitioner's
22 professional practice; or
23 (2) by a practitioner or by the practitioner's authorized agent under
24 such practitioner's supervision for the purpose of or as an incident to
25 research, teaching or chemical analysis or by a pharmacist or medical care
26 facility as an incident to dispensing of a controlled substance.
27 (aa) "Marijuana" means all parts of all varieties of the plant Cannabis
28 whether growing or not, the seeds thereof, the resin extracted from any
29 part of the plant and every compound, manufacture, salt, derivative,
30 mixture or preparation of the plant, its seeds or resin. It does not include:
31 (1) The mature stalks of the plant, fiber produced from the stalks, oil
32 or cake made from the seeds of the plant, any other compound,
33 manufacture, salt, derivative, mixture or preparation of the mature stalks,
34 except the resin extracted therefrom, fiber, oil or cake or the sterilized seed
35 of the plant that is incapable of germination;
36 (2) any substance listed in schedules II through V of the uniform
37 controlled substances act;
38 (3) drug products approved by the United States food and drug
39 administration as of the effective date of this act;
40 (4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-
41 2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or
42 (5) industrial hemp as defined in K.S.A. 2-3901, and amendments
43 thereto, when cultivated, produced, possessed or used for activities

HB 2218 5
1 authorized by the commercial industrial hemp act.
2 (bb) "Medical care facility" shall have the meaning ascribed to that
3 term means the same as defined in K.S.A. 65-425, and amendments
4 thereto.
5 (cc) "Mid-level practitioner" means a certified nurse-midwife
6 engaging in the independent practice of midwifery under the independent
7 practice of midwifery act, an advanced practice registered nurse issued a
8 license pursuant to K.S.A. 65-1131, and amendments thereto, who has
9 authority to prescribe drugs under K.S.A. 65-1130, and amendments
10 thereto, or a physician assistant licensed under the physician assistant
11 licensure act who has authority to prescribe drugs pursuant to a written
12 agreement with a supervising physician under K.S.A. 65-28a08, and
13 amendments thereto.
14 (dd) "Narcotic drug" means any of the following whether produced
15 directly or indirectly by extraction from substances of vegetable origin or
16 independently by means of chemical synthesis or by a combination of
17 extraction and chemical synthesis:
18 (1) Opium and opiate and any salt, compound, derivative or
19 preparation of opium or opiate;
20 (2) any salt, compound, isomer, derivative or preparation thereof that
21 is chemically equivalent or identical with any of the substances referred to
22 in paragraph (1) but not including the isoquinoline alkaloids of opium;
23 (3) opium poppy and poppy straw;
24 (4) coca leaves and any salt, compound, derivative or preparation of
25 coca leaves, and any salt, compound, isomer, derivative or preparation
26 thereof that is chemically equivalent or identical with any of these
27 substances, but not including decocainized coca leaves or extractions of
28 coca leaves that do not contain cocaine or ecgonine.
29 (ee) "Opiate" means any substance having an addiction-forming or
30 addiction-sustaining liability similar to morphine or being capable of
31 conversion into a drug having addiction-forming or addiction-sustaining
32 liability. It does not include, unless specifically designated as controlled
33 under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer
34 of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does
35 include its racemic and levorotatory forms.
36 (ff) "Opium poppy" means the plant of the species Papaver
37 somniferum l. except its seeds.
38 (gg) "Person" means an individual, corporation, government, or
39 governmental subdivision or agency, business trust, estate, trust,
40 partnership or association or any other legal entity.
41 (hh) "Pharmacist" means any natural person licensed under K.S.A.
42 65-1625 et seq., and amendments thereto, to practice pharmacy.
43 (ii) "Pharmacist intern" means: (1) A student currently enrolled in an

HB 2218 6
1 accredited pharmacy program; (2) a graduate of an accredited pharmacy
2 program serving such person's internship; or (3) a graduate of a pharmacy
3 program located outside of the United States that is not accredited and who
4 had successfully passed equivalency examinations approved by the board.
5 (jj) "Pharmacy prescription application" means software that is used
6 to process prescription information, is installed on a pharmacy's computers
7 and servers, and is controlled by the pharmacy.
8 (kk) "Poppy straw" means all parts, except the seeds, of the opium
9 poppy, after mowing.
10 (ll) "Practitioner" means a person licensed to practice medicine and
11 surgery, dentist, podiatrist, veterinarian, optometrist, or scientific
12 investigator or other person authorized by law to use a controlled
13 substance in teaching or chemical analysis or to conduct research with
14 respect to a controlled substance.
15 (mm) "Prescriber" means a practitioner or a mid-level practitioner.
16 (nn) "Production" includes the manufacture, planting, cultivation,
17 growing or harvesting of a controlled substance.
18 (oo) "Psilocybin" does not include the pharmaceutical composition of
19 crystalline polymorph psilocybin, known as COMP 360 or any such trade
20 name approved by the United States food and drug administration.
21 (pp) "Readily retrievable" means that records kept by automatic data
22 processing applications or other electronic or mechanized recordkeeping
23 systems can be separated out from all other records within a reasonable
24 time not to exceed 48 hours of a request from the board or other authorized
25 agent or that hard-copy records are kept on which certain items are
26 asterisked, redlined or in some other manner visually identifiable apart
27 from other items appearing on the records.
28 (pp)(qq) "Ultimate user" means a person who lawfully possesses a
29 controlled substance for such person's own use or for the use of a member
30 of such person's household or for administering to an animal owned by
31 such person or by a member of such person's household.
32 Sec. 2. On and after the date of publication in the Kansas register of
33 the notice prescribed in section 3, K.S.A. 2024 Supp. 65-4111 is hereby
34 amended to read as follows: 65-4111. (a) The controlled substances listed
35 in this section are included in schedule IV and the number set forth
36 opposite each drug or substance is the DEA controlled substances code
37 that has been assigned to it.
38 (b) Any material, compound, mixture or preparation that contains any
39 quantity of the following substances including its salts, isomers and salts
40 of isomers whenever the existence of such salts, isomers and salts of
41 isomers is possible within the specific chemical designation and having a
42 potential for abuse associated with a depressant effect on the central
43 nervous system:

HB 2218 7
1 (1) Alprazolam.............................................................................2882
2 (2) Barbital...................................................................................2145
3 (3) Brexanolone...........................................................................2400
4 (4) Bromazepam .........................................................................2748
5 (5) Camazepam............................................................................2749
6 (6) Carisoprodol...........................................................................8192
7 (7) Chloral betaine.......................................................................2460
8 (8) Chloral hydrate.......................................................................2465
9 (9) Chlordiazepoxide...................................................................2744
10 (10) Clobazam................................................................................2751
11 (11) Clonazepam............................................................................2737
12 (12) Clorazepate.............................................................................2768
13 (13) Clotiazepam............................................................................2752
14 (14) Cloxazolam............................................................................2753
15 (15) Daridorexant...........................................................................2410
16 (16) Delorazepam..........................................................................2754
17 (17) Diazepam................................................................................2765
18 (18) Dichloralphenazone................................................................2467
19 (19) Estazolam...............................................................................2756
20 (20) Ethchlorvynol.........................................................................2540
21 (21) Ethinamate..............................................................................2545
22 (22) Ethyl loflazepate.....................................................................2758
23 (23) Fludiazepam...........................................................................2759
24 (24) Flunitrazepam.........................................................................2763
25 (25) Flurazepam.............................................................................2767
26 (26) Fospropofol............................................................................2138
27 (27) Halazepam..............................................................................2762
28 (28) Haloxazolam..........................................................................2771
29 (29) Ketazolam..............................................................................2772
30 (30) Lemborexant..........................................................................2245
31 (31) Loprazolam............................................................................2773
32 (32) Lorazepam..............................................................................2885
33 (33) Lormetazepam........................................................................2774
34 (34) Mebutamate............................................................................2800
35 (35) Medazepam............................................................................2836
36 (36) Meprobamate..........................................................................2820
37 (37) Methohexital..........................................................................2264
38 (38) Methylphenobarbital (mephobarbital)...................................2250
39 (39) Midazolam..............................................................................2884
40 (40) Nimetazepam..........................................................................2837
41 (41) Nitrazepam.............................................................................2834
42 (42) Nordiazepam..........................................................................2838
43 (43) Oxazepam...............................................................................2835

HB 2218 8
1 (44) Oxazolam...............................................................................2839
2 (45) Paraldehyde............................................................................2585
3 (46) Petrichloral.............................................................................2591
4 (47) Phenobarbital..........................................................................2285
5 (48) Pinazepam..............................................................................2883
6 (49) Prazepam................................................................................2764
7 (50) Quazepam...............................................................................2881
8 (51) Remimazolam........................................................................2846
9 (52) Temazepam.............................................................................2925
10 (53) Tetrazepam.............................................................................2886
11 (54) Triazolam...............................................................................2887
12 (55) Zolpidem................................................................................2783
13 (56) Zaleplon..................................................................................2781
14 (57) Zopiclone................................................................................2784
15 (58) Alfaxalone..............................................................................2731
16 (59) Suvorexant..............................................................................2223
17 (c) Any material, compound, mixture or preparation that contains any
18 quantity of lorcaserin (1625), including its salts, isomers and salts of such
19 isomers, whenever the existence of such salts, isomers and salts of isomers
20 is possible (21 U.S.C. § 812; 21 C.F.R. § 1308.14).
21 (d) Unless specifically excepted or unless listed in another schedule,
22 any material, compound, mixture or preparation that contains any quantity
23 of the following substances having a stimulant effect on the central
24 nervous system, including its salts, isomers (whether optical, position or
25 geometric) and salts of such isomers whenever the existence of such salts,
26 isomers and salts of isomers is possible within the specific chemical
27 designation:
28 (1) Cathine ((+)-norpseudoephedrine).........................................1230
29 (2) Diethylpropion.......................................................................1610
30 (3) Fencamfamin..........................................................................1760
31 (4) Fenproporex...........................................................................1575
32 (5) Mazindol................................................................................1605
33 (6) Mefenorex..............................................................................1580
34 (7) Pemoline (including organometallic
35 complexes and chelates thereof)............................................1530
36 (8) Phentermine............................................................................1640
37 The provisions of subsection (d)(8) shall expire on the date
38 phentermine and its salts and isomers are removed from schedule IV of the
39 federal controlled substances act (21 U.S.C. § 812; 21 C.F.R. § 1308.14).
40 (9) Pipradrol.................................................................................1750
41 (10) Serdexmethylphenidate..........................................................1729
42 (11) SPA((-)-1-dimethylamino-1, 2-diphenylethane)....................1635
43 (12) Sibutramine............................................................................1675

HB 2218 9
1 (13) Solriamfetol (2-amino-3-phenylpropyl carbamate;
2 benzenepropanol, beta-amino-, carbamate (ester))................1650
3 (14) Mondafinil..............................................................................1680
4 (e) Unless specifically excepted or unless listed in another schedule,
5 any material, compound, mixture or preparation that contains any quantity
6 of the following, including salts thereof:
7 (1) Pentazocine............................................................................9709
8 (2) Butorphanol (including its optical isomers)...........................9720
9 (3) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-
10 dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-
11 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its
12 optical isomers) and its salts, isomers, and salts of isomers..9725
13 (f) Unless specifically excepted or unless listed in another schedule,
14 any material, compound, mixture or preparation containing any of the
15 following narcotic drugs, or their salts calculated as the free anhydrous
16 base or alkaloid, in limited quantities as set forth below:
17 (1) Not more than 1 milligram of difenoxin and not less than 25
18 micrograms of atropine sulfate per dosage unit.....................9167
19 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-
20 3-methyl-2-propion-oxybutane).............................................9278
21 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol,
22 its salts, optical and geometric isomers and salts of these isomers
23 (including tramadol)...............................................................9752
24 (g) Butyl nitrite and its salts, isomers, esters, ethers or their salts.
25 (h) Any pharmaceutical composition of crystalline polymorph
26 psilocybin approved by the United States food and drug administration.
27 (i) The board may except by rule and regulation any compound,
28 mixture or preparation containing any depressant substance listed in
29 subsection (b) from the application of all or any part of this act if the
30 compound, mixture or preparation contains one or more active medicinal
31 ingredients not having a depressant effect on the central nervous system,
32 and if the admixtures are included therein in combinations, quantity,
33 proportion or concentration that vitiate the potential for abuse of the
34 substances that have a depressant effect on the central nervous system.
35 New Sec. 3. When the pharmaceutical composition of crystalline
36 polymorph psilocybin is approved as a drug product by the United States
37 food and drug administration, the attorney general shall certify such drug
38 product's approval to the secretary of state within seven days after its
39 approval. Upon receipt of such certification, the secretary of state shall
40 publish such certification in the Kansas register.
41 Sec. 4. On and after the date of publication in the Kansas register of
42 the certification prescribed in section 3, K.S.A. 2024 Supp. 65-4101 and
43 K.S.A. 65-4111 is hereby repealed.

HB 2218 10
1 Sec. 5. This act shall take effect and be in force from and after its
2 publication in the statute book.

[DELETED: AppsrBSo0h1(" ms te dt an of a c2s3t4(5o6(7o8(9t0i1o2(n se p" ms an ey tt s3e4s5t6(7(8t9(0p162(3i4(5t]
[DELETED: 8st(odc4(o0e1d2c344(5(6(7o8(9i0f1r2(3c4t5l6p7(8m9(0a1(" or "" ms te a, ce o2a3w4(5u6i7s8p9(0a1i2(3d]
[DELETED: 8(((ol s n(p(t0(1s2(3a4(5f6c7ie cl i ud or l t be ud i t8m9p0(c p" ms an ey p1p2p3(4t5p6b7(8k9tt is a pr pn as te se of te m0a1a2(3p4e5d6(7g8(e t" or "x t" ms t9t0p1i2p3a]
[DELETED: 8pppp(ts an ec pn bn te pr ad tp((0c1d2i3en ad cl ss ad is ay pg o4r5e6cg of a cd se by an il fr t7i8l9(0o1d2p3(4s5r6f7(8w9p0m1(2or ce me fm te ss of te p, ay or c3m4e5o6(7c8(9a0(122(3t, wn c, p, pd o ud fr a]
[DELETED: 8a(t me  it(l p" ms a cd nepla0t1l2a3a4(5d6i7e8(m ad oe ad ay s, c, de o9p0(1i2i3(4(5c6t7s8c9(0a1c2l3u4o5i6(m p" ms te pt of te ss P7s8(" ms an i, c, g, o9gl sn or a, bs t, e, t0p1(263(]
[DELETED: 8apph(ta(p0(1s, d, p, v, o, or s2ir r r n a bw  ua 3s4r5(6(7g8(9c0n1(2p3s4t5a6a7f8(9c0o1s2S3t4a5i6o7t8(9q0o1i2p3n]
[DELETED: 8()A()B()B()B( C( C( C( C( C0( C1( C2( C3( C4( C5( D6()D7( D8( D9( E0( E1( E2( E3( F4( F5( F6( F7( H8( H9( K0( L1()L2()L3( L4( M5( M6( M7( M8( M9( M0( N1( N2( N3( O]
[DELETED: 8( O( P( P( P( P( P( Q( R( T0( T1( T2( Z3( Z4( Z5( A6( S7(8q9i0i1(2a3o4n5g6i7d8()C9()D0()F1()F2()M3()M4()P5c6()P7Te ps of sn () sl ee on te d8p9f0()P1()S2()S3()S]
[DELETED: 8()Sb()M(ao()P()B()E0d1y2o..3(4a5f6b7()N8m9()D031()22i3(4(5(y pl cn of ce p6p7(8m9s0c1i2a3p4s5N6p7f8p9a0p1S2t3K]
[DELETED: 81Sp]